New York, Feb 26 (Ians) Pharmaceutical companies Pfizer and BioNTech said that they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech Covid-19 vaccine (BNT162b2).
It is to understand the effect of a booster on immunity against Covid-19 caused by the circulating and potential newly emerging Sars-CoV-2 variants, the companies said in a statement on Thursday.
"While we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine, we are taking multiple steps to act decisively and be ready in case a strain becomes resistant to the protection afforded by the vaccine," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
"This booster study is critical to understanding the safety of a third dose and immunity against circulating strains," Bourla added.
The study will draw upon participants from the Phase 1 study in the US
See full article at GlamSham
»
It is to understand the effect of a booster on immunity against Covid-19 caused by the circulating and potential newly emerging Sars-CoV-2 variants, the companies said in a statement on Thursday.
"While we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine, we are taking multiple steps to act decisively and be ready in case a strain becomes resistant to the protection afforded by the vaccine," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
"This booster study is critical to understanding the safety of a third dose and immunity against circulating strains," Bourla added.
The study will draw upon participants from the Phase 1 study in the US